Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- GLs for Ads on Illegal Drugs on Internet to Be Revised
January 25, 2010
- Informed Consent Not Obtained from Many Recipients of Albumin Products
January 25, 2010
- NCs to Take Over Part of Long-Term Debt
January 25, 2010
- Gov't New Growth Strategy to Stimulate Market for OTC Drugs: Mr Hatori
January 25, 2010
- Hisamitsu: Sales Up 5% Driven by Mohrus Series
January 25, 2010
- Korosho to Present Bill to Amend Preventive Vaccination Law
January 25, 2010
- Merck Serono to Increase Market Share for Gonalef, Saizen
January 25, 2010
- Blopress Remains No. 1 for 6 Terms in a Row: Domestic Drugs Sales Ranking
January 25, 2010
- No Serious Concern about Safety of New-Type Flu Vaccines Made in Japan
January 25, 2010
- 26 Listed JPMA Member Companies' Combined Operating Profits Up 28.8% in 1st Half of FY2009
January 25, 2010
- Actemra Approved in the US: Chugai, Roche
January 25, 2010
- Bayer to Transfer Shinbit to Hospira
January 25, 2010
- Pfizer Receives CRL for Lyrica Applied for GAD
January 25, 2010
- Ranbaxy Creates Japanese Subsidiary
January 25, 2010
- Nichi-Iko to Enter the Market for Biosimilars: President Tamura
January 25, 2010
- Mitsui & Co. Embarks on CRO Business in Asia
January 25, 2010
- Latanoprost to See Generics from 23 Companies
January 25, 2010
- New Premium to Trouble Wholesalers Again
January 25, 2010
- Include Prevnar in Periodic Immunization Programs ASAP: Dr Wada
January 25, 2010
- Rate of New Premium for New Drug Development Will Be 5.10%
January 25, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…